Subscribe To
Usd/jpy daily outlook
Daily Pivots: (S1) 139.03; (P) 139.55; (R1) 140.49; More… Intraday bias in USD/JPY stays neutral as consolidation from 140.90 is extending. Further ...
June 5, 2023, 6:32 am
Gbil: shifting to longer-term maturities
Adding 10-year Treasuries to portfolios as inflation potentially peaks and economic indicators point to a cooling economy and softer labor market. The...
June 5, 2023, 3:06 am
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...
June 3, 2023, 8:00 pm
Ceo francis dufay pivoting jumia amidst challenging macroeconomic conditions
Jumia Technologies is focusing on long-term growth strategies, including expanding into secondary cities in Africa and addressing pent-up demand for e...
June 3, 2023, 5:26 am
Gbp/usd mid-day outlook
Daily Pivots: (S1) 1.2438; (P) 1.2489; (R1) 1.2577; More… Intraday bias in GBP/USD stays mildly on the upside at this point. Rebound from 1.2306 is ...
June 2, 2023, 1:23 pm
Usd/jpy mid-day outlook
Daily Pivots: (S1) 138.19; (P) 139.07; (R1) 139.68; More… Intraday bias in USD/JPY remains neutral as range trading continues. Downside of retreat s...
June 2, 2023, 1:19 pm
Pound sterling price news and forecast: gbp/usd forecast – 1.2580 aligns as next bullish target
Bulls cracked pivotal Fibo barrier at 1.2538 (61.8% of 1.2679/1.2310 pullback) with break here to add to positive signals and unmask key barrier at 1....
June 2, 2023, 1:14 pm
Usd/chf mid-day outlook
Daily Pivots: (S1) 0.9034; (P) 0.9076; (R1) 0.9097; More… USD/CHF recovers ahead of 0.9013 minor support but stays below 0.9146 temporary top. Intra...
June 2, 2023, 1:04 pm